Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

Trial Profile

Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Prednisone; Procarbazine
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Nov 2017 Primary endpoint has been met. (Complete remission rate (CR/CRr) as final treatment outcome after completion of treatment) as per result published in the Lancet Oncology.
    • 10 Nov 2017 Results published in the Lancet Oncology
    • 10 May 2017 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top